How It Works
PT-141, known generically as bremelanotide and marketed as Vyleesi, is a synthetic cyclic heptapeptide melanocortin receptor agonist. It was originally derived from the tanning peptide Melanotan II but developed specifically for its effects on sexual function. In 2019, the FDA approved bremelanotide (Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Unlike PDE5 inhibitors (sildenafil, tadalafil) that act on peripheral blood flow, PT-141 works centrally through activation of melanocortin-4 receptors (MC4R) in the hypothalamus. This receptor system plays a key role in regulating sexual desire, arousal, and reward pathways. By activating MC4R, PT-141 stimulates dopaminergic pathways involved in sexual motivation — addressing the desire component of sexual dysfunction rather than mechanical erectile function alone.
This central mechanism of action makes PT-141 effective for both men and women, and particularly useful in cases where vascular-based treatments have been insufficient or where the primary issue is reduced libido rather than erectile function.
Benefits
- FDA approved for HSDD in premenopausal women (as Vyleesi)
- Increases sexual desire through central nervous system pathways
- Effective in both men and women — addresses desire rather than just function
- Works independently of the vascular system — useful when PDE5 inhibitors are contraindicated
- On-demand dosing — no daily commitment required
Side Effects
- Nausea — the most common side effect, reported in approximately 40% of clinical trial participants (usually transient, lasting 1-2 hours)
- Flushing — warmth and redness of the face and upper body
- Headache — reported in approximately 10% of users
- Injection site reactions — pain, redness, bruising at injection site
- Transient blood pressure elevation — typically mild and self-resolving
- Skin hyperpigmentation — possible with repeated use (related to melanocortin activation)
- Not recommended for use more than 8 times per month per prescribing guidelines
Dosing Protocol
| Parameter | Details |
|---|---|
| Standard Dose | 1.75mg (FDA-approved dose); 1-2mg commonly used |
| Frequency | As needed, at least 45 minutes before activity |
| Administration | Subcutaneous injection (abdomen or thigh) |
| Cycle Length | As needed; not to exceed 8 doses per month |
| Titration | Start at 1mg to assess tolerance (nausea risk) |
What You Will Need
- PT-141 auto-injector (Vyleesi, prescription) or lyophilized vial (compounding pharmacy)
- Bacteriostatic water (if reconstituting from vial)
- Insulin syringes (1mL, 29-31ga)
- Alcohol swabs
- Anti-nausea medication (ondansetron) may be helpful for first use